Antimicrobial Agents Practice Questions

Q: Which of the following is used in the prophylaxis of meningococcus?

Rifampicin. ***Rifampicin*** - **Rifampicin** is a recommended agent for **chemoprophylaxis** against **meningococcal disease**, especially for close contacts of patients. - It works by eliminating the carriage of *Neisseria meningitidis* in the **nasopharynx**. *Erythromycin* - **Erythromycin** is a **macrolide antibiotic** primarily used for respiratory tract infections and certain skin infections. - It is **not effective** for the prophylaxis of meningococcal disease due to poor penetration into the nasopharynx and varied efficacy against *N. meningitidis*. *Tetracycline* - **Tetracyclines** are broad-spectrum antibiotics, but they are **not typically used** for meningococcal prophylaxis. Resistance is common [1], and other agents are preferred due to better efficacy and lower risk of side effects in this context. *Penicillin* - **Penicillin** is effective for treating **active meningococcal infection** but is **not suitable for prophylaxis**. - It does not consistently eradicate the carrier state of *N. meningitidis* from the nasopharynx, which is essential for prophylaxis.

Q: The following are live attenuated vaccines, except:

Pertussis. ***Pertussis*** - The **pertussis vaccine** is an **inactivated (subunit) vaccine**, not a live attenuated vaccine. It contains purified components of the *Bordetella pertussis* bacteria. - Due to the high risk of severe complications, especially in infants, an inactivated vaccine is preferred to avoid any risk of active infection from a live vaccine. *BCG* - The **BCG (Bacille Calmette-Guérin) vaccine** is a **live attenuated vaccine** used to prevent tuberculosis. - It contains a live, weakened strain of *Mycobacterium bovis*. *Oral typhoid* - The **oral typhoid vaccine (Ty21a)** is a **live attenuated vaccine** designed to protect against *Salmonella Typhi*. - It consists of a live, weakened strain of the typhoid bacterium, taken orally. *Measles* - The **measles vaccine** (often given as part of the MMR vaccine) is a **live attenuated vaccine**. - It contains a weakened form of the measles virus, eliciting a strong immune response.

Q: Why is a regimen of four drugs recommended for a TB patient on the first visit?

To prevent emergence of drug-resistant strains. ***To prevent emergence of drug-resistant strains*** - Using a **four-drug regimen** at the initial stage significantly reduces the likelihood of **Mycobacterium tuberculosis** developing resistance to any single drug. - This strategy ensures that even if a small number of bacteria are naturally resistant to one drug, the other drugs will still be effective in killing them, preventing the proliferation of **resistant strains**. *To minimize treatment duration* - While a multi-drug regimen is effective, its primary goal is not to minimize treatment duration but rather to ensure **eradication of the infection** and prevent resistance. - Treatment duration is determined by the need to kill both actively multiplying and dormant bacteria, which typically takes several months even with multiple drugs. *To reduce bacterial load effectively* - Reducing bacterial load is certainly a goal of TB treatment, but the use of four drugs is specifically aimed at achieving this while simultaneously preventing **drug resistance**. - A single effective drug could reduce bacterial load, but it would quickly lead to the emergence of resistant bacteria, making the long-term goal of **cure** impossible. *None of the options* - This option is incorrect because the primary reason for a **four-drug regimen** in TB treatment is indeed to prevent the emergence of **drug-resistant strains**.

Q: Which of the following is the treatment of choice for cryptococcal meningitis?

Amphotericin B. ***Amphotericin B*** - **Amphotericin B** is the **primary first-line antifungal agent** for severe fungal infections, including **cryptococcal meningitis**. - Current guidelines recommend **combination therapy with Amphotericin B plus Flucytosine** for induction therapy, with Amphotericin B being the **most critical component**. - Its broad spectrum of activity and ability to penetrate the **blood-brain barrier** make it highly effective against *Cryptococcus neoformans*. - **Liposomal Amphotericin B** is preferred due to reduced nephrotoxicity. *Fluconazole* - **Fluconazole** is an antifungal used for the **consolidation and maintenance phases** of cryptococcal meningitis treatment after initial induction therapy with Amphotericin B. - It is **not adequate as monotherapy** for the initial, acute management of severe cryptococcal meningitis due to slower fungicidal activity compared to Amphotericin B. *Itraconazole* - **Itraconazole** has **poor CNS penetration** and is generally **not recommended** for cryptococcal meningitis. - It is used for other fungal infections but is not part of standard treatment protocols for cryptococcal meningitis. *Flucytosine* - **Flucytosine** is an antifungal that is **always used in combination with Amphotericin B** (never alone) for cryptococcal meningitis to achieve a **synergistic effect** and improve outcomes. - It is **not used as monotherapy** because of rapid development of resistance when used alone. - While combination therapy is the gold standard, **Amphotericin B remains the primary agent**, making it the treatment of choice.

Q: Which of the following aminoglycoside antibiotics has the highest risk of causing ototoxicity?

Neomycin. ***Neomycin*** - **Neomycin** has the highest risk of **ototoxicity** among the aminoglycosides due to its significant accumulation in inner ear fluid. - It is typically reserved for **topical** or **oral administration** for local effects (e.g., bowel decontamination) to minimize systemic absorption and ototoxic risk [2]. *Kanamycin* - **Kanamycin** is an aminoglycoside with significant ototoxic potential, especially with prolonged use or high doses [1]. - While ototoxic, its risk is generally considered to be lower than Neomycin, which is rarely used systemically due to toxicity [1]. *Amikacin* - **Amikacin** is an aminoglycoside known for its broad spectrum of activity against resistant gram-negative bacteria, and it also carries a risk of ototoxicity [4]. - It is often used in severe infections, and its risk of ototoxicity is monitored, but it's not as high as neomycin [4]. *Gentamicin* - **Gentamicin** is a commonly used aminoglycoside for treating serious bacterial infections, and ototoxicity is a known adverse effect [3]. - While ototoxic, its relative risk is considered lower than neomycin and comparable to other commonly used aminoglycosides when therapeutic drug monitoring is employed [3].

Q: A patient diagnosed as having ventilator-associated pneumonia is on treatment with ceftriaxone and amikacin. Culture and sensitivity turned out to be positive for ESBL-producing Klebsiella infection. The most appropriate next action should be:

Change over to imipenem. ***Change over to imipenem*** - **ESBL-producing bacteria** are resistant to most beta-lactam antibiotics, including ceftriaxone. **Carbapenems** like imipenem are the drugs of choice for severe infections caused by ESBL producers. - Switching to imipenem provides **effective empirical coverage** given the updated culture and sensitivity results, ensuring appropriate treatment for the multidrug-resistant organism. *Continue same antibiotic but at higher dose* - ESBL-producing bacteria are **resistant to ceftriaxone**, making it ineffective even at higher doses. - Increasing the dose of an ineffective antibiotic delays appropriate treatment and contributes to **antibiotic resistance**. *Replace ceftriaxone with ceftazidime* - Ceftazidime is also a **third-generation cephalosporin** and is generally ineffective against ESBL-producing organisms. - Switching to another cephalosporin would represent a continuation of **inappropriate antibiotic therapy**. *Remove amikacin and add quinolone* - While quinolones may have activity against some Gram-negative bacteria, their effectiveness against **ESBL-producing Klebsiella** is variable and often compromised by resistance. - **Amikacin** (an aminoglycoside) is a broad-spectrum antibiotic often used in combination for severe infections, and its removal without clear resistance or adverse effects may reduce coverage, especially for synergistic effects against multidrug-resistant organisms.

Q: All of the following beta-lactam antibiotics possess antipseudomonal action, except:

Ceftriaxone. ***Ceftriaxone*** - **Ceftriaxone** is a third-generation cephalosporin that has broad-spectrum activity but **lacks reliable antipseudomonal activity**. - While effective against many **Gram-positive** and **Gram-negative bacteria**, it is not a recommended choice for treating **Pseudomonas aeruginosa infections**. *Piperacillin* - **Piperacillin** is an extended-spectrum penicillin (often combined with **tazobactam**) known for its potent activity against **Pseudomonas aeruginosa**. - It is frequently used in empirical treatment of severe infections where **pseudomonal coverage** is critical. *Ceftazidime* - **Ceftazidime** is a third-generation cephalosporin specifically developed to have strong activity against **Pseudomonas aeruginosa**. - It is a key antibiotic in the treatment of **pseudomonal infections**, particularly those affecting the **lungs** or **urinary tract**. *Cefoperazone* - **Cefoperazone** is a third-generation cephalosporin that demonstrates good antipseudomonal activity, especially when combined with a **beta-lactamase inhibitor** like **sulbactam**. - It is used in the treatment of various infections caused by **P. aeruginosa** and other **Gram-negative bacteria**.

Q: Rifampicin acts by inhibiting which of the following?

DNA Dependent RNA polymerase. ***DNA Dependent RNA polymerase*** - **Rifampicin** works by binding to the **beta-subunit** of bacterial **DNA-dependent RNA polymerase**, preventing the initiation of RNA synthesis [2]. - This action is **bactericidal** and is crucial for its effectiveness against **Mycobacterium tuberculosis** and other bacteria [2]. *RNA dependent DNA polymerase* - This enzyme is also known as **reverse transcriptase** and is found in **retroviruses**, not bacteria [1]. - While it is a target for antiretroviral drugs, it is **not the target of rifampicin** [1]. *Mycolic acid inhibition* - **Mycolic acid** synthesis is a target for antitubercular drugs like **isoniazid**, which inhibits **mycolic acid production**. - Rifampicin does **not directly inhibit mycolic acid synthesis** but rather interferes with RNA transcription. *Mycolic acid incorporation defects* - This mechanism is characteristic of drugs like **ethambutol**, which interferes with the **polymerization of arabinogalactan**, thus hindering the proper incorporation of mycolic acid into the cell wall. - Rifampicin's mechanism of action is **distinct** from interfering with mycolic acid incorporation.

Q: What are the types of HPV vaccines that have been licensed and are available?

Bivalent, Quadrivalent, and Nonavalent. ***Bivalent, Quadrivalent, and Nonavalent*** - Three types of HPV vaccines have been licensed: **bivalent** (2vHPV, Cervarix), **quadrivalent** (4vHPV, Gardasil), and **nonavalent** (9vHPV, Gardasil 9). - The **bivalent vaccine** protects against HPV types 16 and 18 (responsible for ~70% of cervical cancers). - The **quadrivalent vaccine** protects against HPV types 6, 11, 16, and 18 (also covers genital warts). - The **nonavalent vaccine** protects against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58) and is currently the most widely used, offering the broadest protection. *Monovalent* - This term refers to a vaccine targeting only **one specific strain** of a pathogen. - No HPV vaccine has ever been licensed as monovalent, as even the earliest vaccines covered multiple high-risk types. *Trivalent* - This describes a vaccine protecting against **three different strains** of a pathogen. - No **trivalent HPV vaccine** has ever been developed or licensed. *Only Quadrivalent* - While the **quadrivalent vaccine (Gardasil)** was an important advancement, it is not the only type available. - Both **bivalent** and **nonavalent** vaccines are also licensed and available globally.

Question 1

Which of the following is used in the prophylaxis of meningococcus?

Accepted Answer

Rifampicin

Answer

Tetracycline

Answer

Erythromycin

Answer

Penicillin

Question 2

The following are live attenuated vaccines, except:

Accepted Answer

Pertussis

Answer

BCG

Answer

Oral typhoid

Answer

Measles

Question 3

Why is a regimen of four drugs recommended for a TB patient on the first visit?

Accepted Answer

To prevent emergence of drug-resistant strains

Answer

To reduce bacterial load effectively

Answer

To minimize treatment duration

Answer

None of the options

Question 4

Which of the following is the treatment of choice for cryptococcal meningitis?

Accepted Answer

Amphotericin B

Answer

Fluconazole

Answer

Itraconazole

Answer

Flucytosine

Question 5

Which of the following aminoglycoside antibiotics has the highest risk of causing ototoxicity?

Accepted Answer

Neomycin

Answer

Amikacin

Answer

Kanamycin

Answer

Gentamicin

Question 6

A patient diagnosed as having ventilator-associated pneumonia is on treatment with ceftriaxone and amikacin. Culture and sensitivity turned out to be positive for ESBL-producing Klebsiella infection. The most appropriate next action should be:

Accepted Answer

Change over to imipenem

Answer

Continue same antibiotic but at higher dose

Answer

Remove amikacin and add quinolone

Answer

Replace ceftriaxone with ceftazidime

Question 7

All of the following beta-lactam antibiotics possess antipseudomonal action, except:

Accepted Answer

Ceftriaxone

Answer

Ceftazidime

Answer

Cefoperazone

Answer

Piperacillin

Question 8

Rifampicin acts by inhibiting which of the following?

Accepted Answer

DNA Dependent RNA polymerase

Answer

RNA dependent DNA polymerase

Answer

Mycolic acid inhibition

Answer

Mycolic acid incorporation defects

Question 9

What are the types of HPV vaccines that have been licensed and are available?

Accepted Answer

Bivalent, Quadrivalent, and Nonavalent

Answer

Monovalent

Answer

Trivalent

Answer

Only Quadrivalent

Question 10

A 30-year-old female patient complains of a cough with sputum, and is a known case of tuberculosis who is currently taking rifampin for the same. All of the following are true about this drug except:

Accepted Answer

It binds with the alpha-subunit of prokaryotic RNA polymerase

Answer

It inhibits transcription

Answer

It binds with the beta-subunit of prokaryotic RNA polymerase

Answer

It is metabolized by CYP450 enzymes

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?